Speaking on the commencement of the clinical trials, which have been approved by the Drugs Control General India (DCGI), Siddharth Daga, Chief Executive Officer, VINS Bioproducts Limited said, “The development of VINCOV-19, in partnership with the Centre for Cellular and Molecular Biology and the University of Hyderabad and under the aegis of the Indian Council of Medical Research (ICMR), is a significant breakthrough in the fight against Covid-19. We feel extremely privileged that we have been able to use our collective resources and expertise in developing this cure and are proud to lead this fight against Covid-19.”